Stifel Nicolaus Reaffirms “Buy” Rating for Celcuity (NASDAQ:CELC)

Stifel Nicolaus reaffirmed their buy rating on shares of Celcuity (NASDAQ:CELCFree Report) in a research note published on Thursday, Benzinga reports. The firm currently has a $40.00 price target on the stock.

Several other research firms also recently weighed in on CELC. Needham & Company LLC reaffirmed a buy rating and issued a $24.00 target price on shares of Celcuity in a research report on Thursday. Craig Hallum restated a buy rating and issued a $27.00 price objective (up previously from $25.00) on shares of Celcuity in a report on Thursday. Finally, HC Wainwright reiterated a buy rating and set a $27.00 target price on shares of Celcuity in a report on Thursday.

Read Our Latest Analysis on CELC

Celcuity Stock Performance

Shares of Celcuity stock opened at $16.76 on Thursday. The firm has a market cap of $523.41 million, a PE ratio of -6.03 and a beta of 0.87. The company has a quick ratio of 13.43, a current ratio of 11.23 and a debt-to-equity ratio of 0.28. Celcuity has a 52 week low of $8.39 and a 52 week high of $22.19. The business’s fifty day simple moving average is $17.95 and its 200-day simple moving average is $15.66.

Celcuity (NASDAQ:CELCGet Free Report) last posted its earnings results on Wednesday, March 27th. The company reported ($0.65) EPS for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.06. Equities analysts forecast that Celcuity will post -2.93 earnings per share for the current year.

Institutional Trading of Celcuity

A number of large investors have recently modified their holdings of the stock. Pale Fire Capital SE acquired a new position in shares of Celcuity during the third quarter worth $95,000. SG Americas Securities LLC purchased a new stake in shares of Celcuity in the fourth quarter valued at about $139,000. Trust Point Inc. purchased a new stake in shares of Celcuity in the fourth quarter valued at about $297,000. Commodore Capital LP raised its holdings in shares of Celcuity by 3.6% in the fourth quarter. Commodore Capital LP now owns 1,754,704 shares of the company’s stock valued at $25,566,000 after buying an additional 60,563 shares during the last quarter. Finally, Perceptive Advisors LLC purchased a new stake in shares of Celcuity in the fourth quarter valued at about $21,583,000. Hedge funds and other institutional investors own 63.33% of the company’s stock.

Celcuity Company Profile

(Get Free Report)

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.

See Also

Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.